Zevalin® (ibritumomab tiuxetan)

For further information, please see the Injectable drugs page.

Code(s): A9543

Benefit: Medical

Notes: Radioimmunotherapy; indicated for the treatment of relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma (NHL)

Criteria for coverage:

  • See PA form for criteria for Commercial and Medicaid

  • Refer to CMS local coverage determination criteria for Part B when available.